Emcure Pharmaceuticals Limited — Financials & Forensics
Sector: Healthcare · NSE: EMCURE · BSE: 544210 · ISIN: INE168P01015
18 Aug 2026
Add EMCURE to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY25 | FY26 |
|---|---|---|
| Revenue from operations | ₹7,896 Cr | ₹9,204 Cr |
| EBITDA | ₹1,474 Cr | ₹1,865 Cr |
| EBITDA margin | 18.7% | 20.3% |
| Profit after tax | ₹707 Cr | ₹941 Cr |
Deeper analysis
Recent filings by Emcure Pharmaceuticals Limited
-
Transcript of Earnings Call - Q1 FY27
12 Aug 2026 · Financial Results
-
General Updates
08 Aug 2026 · Regulatory Compliance
-
Analyst/Investor Meet on Wednesday, August 12, 2026
07 Aug 2026 · General Update
-
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2
07 Aug 2026 · Regulatory Compliance
-
Analysts/Institutional Investor Meet/Con. Call Updates
06 Aug 2026 · General Update
Never miss a filing again
About Emcure Pharmaceuticals Limited on Indian Stock Alerts
Indian Stock Alerts tracks Emcure Pharmaceuticals Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.